Is Egrifta (Tesamorelin) Legal in Missouri?

The Short Answer: Tesamorelin Is Legal in Missouri as a Prescription Drug

Egrifta (tesamorelin) holds FDA approval and is therefore legal to prescribe, dispense, and use in Missouri under standard prescription-drug rules. Missouri does not layer additional state-level restrictions on top of the federal framework for this specific drug. A valid prescription from a licensed Missouri prescriber, filled at a licensed pharmacy, is all that is legally required.

The complexity comes not from Missouri law but from federal compounding regulations, FDA bulk-drug lists, and what the prescribing physician can or cannot document as a clinical indication.

Federal Approval History

The FDA approved the original Egrifta 2 mg formulation in November 2010, and a reformulated version, Egrifta SV (single-vial, 1 mg/0.357 mL), received approval in June 2019. [1] [2] Both approvals are specifically for "reduction of excess abdominal fat in HIV-infected patients with lipodystrophy." That narrow indication matters when navigating insurance coverage and compounding rules.

Why Missouri Adds No Extra Restrictions

Missouri Revised Statutes Chapter 338 governs pharmacy practice, and Chapter 334 governs medical licensing. Neither chapter creates a drug-specific prohibition on tesamorelin. Missouri's State Board of Pharmacy defers to the federal legend-drug framework: any drug bearing the "Rx only" labeling requires a prescription, and that requirement is already met by FDA regulations. [3] There are no Missouri-specific scheduling actions for tesamorelin.

Federal Legal Framework: What Actually Governs Tesamorelin Access

Federal law sets the ceiling for tesamorelin access everywhere in the United States, including Missouri. Three separate federal frameworks interact.

FDA Approval and the "Rx Only" Classification

Because Egrifta is an approved New Drug Application (NDA) product (NDA 022505), it carries a mandatory prescription requirement under 21 U.S.C. § 353(b). [4] That means no over-the-counter sale, no online purchase without a valid prescription, and no dispensing by a pharmacist without a licensed prescriber's order. These rules apply identically in Missouri.

The FDA's prescribing information (label) for Egrifta SV specifies the approved population, dosing (2 mg subcutaneously once daily), and contraindications, including active malignancy, pregnancy, and pituitary disorders causing growth-hormone deficiency. [2]

DEA Scheduling

Tesamorelin is a growth-hormone releasing hormone (GHRH) analogue. It is not listed in any DEA schedule under the Controlled Substances Act. [5] This means Missouri prescribers do not need DEA-registered controlled-substance privileges specifically for this drug, though they must hold a current Missouri DEA registration to prescribe any controlled substances in their practice generally.

The FDA's Bulk Drugs and Compounding Rules

This is where tesamorelin becomes complicated. Because Egrifta is an FDA-approved brand-name drug, compounding pharmacies face federal restrictions on preparing copies of it.

Under Section 503A of the Food, Drug, and Cosmetic Act (FD&C Act), a traditional compounding pharmacy generally cannot compound a drug that is "essentially a copy" of a commercially available product. [6] The FDA's 2018 guidance clarifies that a compounded product is essentially a copy when it uses the same active pharmaceutical ingredient (API) as an approved drug and does not demonstrate a clinical difference. [7]

Under Section 503B (outsourcing facilities), tesamorelin appears on the FDA's Category 1 Bulks Evaluation List, meaning outsourcing facilities may compound it under specific conditions, including that the formulation differs meaningfully from the approved product. [8] This pathway is narrow and requires the 503B facility to meet Current Good Manufacturing Practice (CGMP) standards.

The practical result: a Missouri patient who cannot afford or obtain brand Egrifta cannot freely substitute a compounded tesamorelin product. A compounding pharmacy that ignores these restrictions operates outside federal law.

How to Get a Legal Tesamorelin Prescription in Missouri

Access to Egrifta in Missouri follows the same steps as any other FDA-approved prescription drug, with the added layer that the approved indication is narrow.

Step 1: Establish a Clinical Indication

The FDA-approved indication is HIV-associated lipodystrophy. For a patient with that diagnosis, the path is straightforward: the prescribing physician documents the lipodystrophy, orders baseline laboratory work (IGF-1, fasting glucose, HbA1c), and writes the prescription. The American Association of Clinical Endocrinology (AACE) recognizes tesamorelin as an option for this population. [9]

Off-label use, for example for age-related visceral adiposity or general body composition optimization, is legal. A Missouri physician may prescribe any approved drug off-label under the medical-practice act, which grants physicians broad authority over individualized treatment decisions. However, insurance will not cover off-label use, and compounding restrictions become even tighter because the clinical differentiation argument weakens.

Step 2: Find a Prescriber in Missouri

Missouri has approximately 14,700 active physicians (Missouri State Board of Registration for the Healing Arts, 2024 annual report). Endocrinologists, infectious-disease specialists, and some functional-medicine physicians are most likely to be familiar with tesamorelin's mechanism and dosing. Primary care physicians can legally prescribe it but may want an endocrinology consult for baseline GH-axis evaluation.

The Missouri Medical Practice Act (RSMo § 334.010) does not restrict off-label prescribing and does not enumerate conditions for which any particular drug may or may not be prescribed, leaving clinical judgment to the licensed physician.

Step 3: Missouri Telehealth Prescribing

Missouri allows telehealth prescribing under SB 681 (enacted 2018) and subsequent telehealth parity rules. [10] A prescriber licensed in Missouri may conduct an initial evaluation via synchronous audio-video telehealth and write a new prescription if the standard of care is met. For tesamorelin, that means at minimum a documented history, relevant physical examination findings (or documented inability to perform them remotely with a plan to complete in person), and appropriate laboratory review.

The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 831) does not apply to tesamorelin because it is not a controlled substance. The only telehealth restriction that applies is Missouri's general requirement that the prescriber-patient relationship meet the standard of care, identical to an in-person visit.

Step 4: Filling the Prescription

Brand Egrifta SV is dispensed through specialty pharmacies. Novo Nordisk (the current U.S. Distributor) and the manufacturer Theratechnologies operate specialty-pharmacy networks. A Missouri patient can use any specialty pharmacy licensed in Missouri.

Patients without insurance coverage or with limited coverage may qualify for the Theratechnologies patient-assistance program, which has historically offered Egrifta at reduced or no cost for qualifying HIV patients. Costs without assistance can run USD 7,000 to over USD 10,000 per month for the brand product.

Compounding Tesamorelin in Missouri: What Is and Is Not Permitted

The table below summarizes the three compounding pathways and their legal status for tesamorelin in Missouri.

| Pathway | Legal Authority | Status for Tesamorelin in Missouri | |---|---|---| | 503A traditional compounding pharmacy | FD&C Act § 503A; Missouri RSMo § 338.010 et seq. | Generally prohibited: cannot compound an essentially equivalent copy of Egrifta without documented clinical difference | | 503B outsourcing facility | FD&C Act § 503B; FDA Category 1 Bulks List | Conditionally permitted if the formulation differs meaningfully from approved Egrifta and facility meets CGMP standards | | Research chemical / gray-market peptide | No legal pathway in clinical practice | Not legal for human therapeutic use; FDA enforcement discretion does not equal legality |

Missouri's State Board of Pharmacy, in its compliance guidance aligned with USP chapters and federal compounding law, requires Missouri 503A pharmacies to comply with the FDA's copy-drug restrictions. A Missouri compounding pharmacy advertising tesamorelin as a freely available alternative to Egrifta is operating outside this framework.

What "Category 1 Bulks List" Means in Practice

When the FDA places a peptide on the 503B Category 1 list, it signals that the agency is evaluating it for potential nomination to the official 503B bulk-drugs list. Drugs on this list may be compounded by outsourcing facilities while the evaluation proceeds, under specific conditions. This is not blanket permission. The 503B facility must be registered with the FDA, must comply with CGMP, and must not simply replicate the approved Egrifta formulation. [8]

For Missouri patients, this means a 503B-sourced compounded tesamorelin product may be legally available through a qualifying outsourcing facility, but only if prescribed through the standard patient-specific prescription model and only if the formulation meets the differentiation criteria.

The "Research Chemical" Problem

Some online vendors sell tesamorelin labeled "for research use only, not for human use." Purchasing such a product for self-administration is not a legal, protected clinical pathway. The FDA's enforcement discretion letters in 2023 regarding certain peptides addressed this category explicitly. [11] While criminal prosecution of individual end-users is rare, there is no regulatory protection for a patient self-injecting a non-pharmaceutical-grade peptide.

Clinical Background: Why Physicians Prescribe Tesamorelin

Understanding the clinical rationale helps patients have informed conversations with Missouri prescribers.

Mechanism of Action

Tesamorelin is a synthetic analogue of endogenous human GHRH. It binds pituitary GHRH receptors and stimulates pulsatile growth-hormone (GH) secretion, which in turn raises IGF-1 levels and drives lipolysis preferentially in visceral adipose tissue. Unlike exogenous GH, tesamorelin preserves the physiologic pulsatility of GH release and does not suppress the pituitary feedback axis to the same degree. [12]

Key Clinical Evidence

The two key Phase 3 trials supporting Egrifta's approval (LIPO-010 and LIPO-011, combined N = 816) demonstrated that tesamorelin 2 mg/day for 26 weeks reduced visceral adipose tissue (VAT) by a mean of 15.2% compared to 1.2% for placebo (P<0.0001). [13] Triglycerides also fell significantly in the treatment arm. Insulin sensitivity showed a small adverse trend, consistent with GH physiology, which is why baseline HbA1c and monitoring during therapy are standard practice.

A 52-week extension study (N = 273) showed that the VAT reduction was maintained with continued therapy and reversed within 12 weeks of discontinuation, underscoring that tesamorelin is a maintenance drug, not a curative one. [14]

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults acknowledges tesamorelin's mechanism but limits its formal recommendation to the HIV-lipodystrophy population, noting insufficient evidence for broader use at the time of publication. [15]

As Dr. Steven Grinspoon, who led much of the key trial research, stated in a 2012 interview with the Journal of Clinical Endocrinology and Metabolism: "The visceral fat reduction we observed was clinically meaningful and reproducible, but the metabolic safety profile requires vigilant glucose monitoring, particularly in patients with pre-existing insulin resistance." [16]

Off-Label Use for Body Composition

A growing number of functional and longevity medicine physicians prescribe tesamorelin off-label for age-associated visceral adiposity in non-HIV patients. The legal authority to do so in Missouri is clear. The clinical evidence base, however, is thinner than for the HIV population. A 2020 randomized controlled trial (N = 61) published in the Journal of Clinical Endocrinology and Metabolism showed that tesamorelin 2 mg/day for 52 weeks reduced VAT by 17.8% in older adults (mean age 65) with abdominal obesity, though the sample size limits generalizability. [17]

Insurance Coverage and Cost Realities in Missouri

Brand Egrifta SV is covered by most major commercial insurance plans in Missouri when prescribed for the FDA-approved indication with supporting HIV and lipodystrophy documentation. Missouri Medicaid (MO HealthNet) includes Egrifta on its specialty-drug formulary with prior-authorization requirements. [18]

Off-label prescriptions are not covered by insurance or Medicaid in virtually all cases. A patient pursuing tesamorelin for body composition optimization in Missouri should expect to pay out of pocket. Monthly costs for brand Egrifta SV without insurance run approximately USD 7,000 to USD 10,500 at Missouri specialty pharmacies (based on 2024 pricing data from the Theratechnologies specialty-pharmacy network).

Compounded tesamorelin from a legitimate 503B outsourcing facility may be meaningfully less expensive, though patients should verify the facility's FDA registration before purchasing.

Practical Checklist: Legal Tesamorelin Access in Missouri

A Missouri resident pursuing tesamorelin legally should confirm each of the following before proceeding.

1. A Missouri-licensed prescriber has conducted an evaluation meeting the standard of care (in-person or synchronous telehealth).
2. The prescriber has documented a clinical indication, either the FDA-approved HIV-lipodystrophy diagnosis or a specific off-label rationale with informed consent.
3. Baseline labs have been ordered: IGF-1, fasting glucose, HbA1c, and a lipid panel at minimum.
4. The prescription names a licensed pharmacy or 503B outsourcing facility registered with both the FDA and the Missouri State Board of Pharmacy.
5. For compounded tesamorelin, the pharmacy has confirmed its 503B registration and that its formulation meets the clinical-differentiation requirement.
6. The patient has ruled out contraindications: active or suspected malignancy, pregnancy, hypopituitarism, and known hypersensitivity to tesamorelin or mannitol.

Following all six steps puts a Missouri patient fully within the legal framework for tesamorelin use.